300267 Stock Overview
Manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Hunan Er-Kang Pharmaceutical Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥2.26 |
52 Week High | CN¥3.93 |
52 Week Low | CN¥2.03 |
Beta | 0.23 |
11 Month Change | 1.35% |
3 Month Change | -5.83% |
1 Year Change | -30.46% |
33 Year Change | -42.20% |
5 Year Change | -58.30% |
Change since IPO | -6.92% |
Recent News & Updates
What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You
Aug 08Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?
Jun 03Recent updates
Shareholder Returns
300267 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 4.6% | 0.5% | -0.8% |
1Y | -30.5% | -12.3% | -13.4% |
Return vs Industry: 300267 underperformed the CN Pharmaceuticals industry which returned -12.3% over the past year.
Return vs Market: 300267 underperformed the CN Market which returned -13.4% over the past year.
Price Volatility
300267 volatility | |
---|---|
300267 Average Weekly Movement | 8.0% |
Pharmaceuticals Industry Average Movement | 5.3% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.8% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300267 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300267's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 1,497 | Qingrong Sun | www.hnerkang.com |
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company’s finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets.
Hunan Er-Kang Pharmaceutical Co., Ltd Fundamentals Summary
300267 fundamental statistics | |
---|---|
Market cap | CN¥4.58b |
Earnings (TTM) | -CN¥240.97m |
Revenue (TTM) | CN¥1.35b |
3.4x
P/S Ratio-19.3x
P/E RatioIs 300267 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300267 income statement (TTM) | |
---|---|
Revenue | CN¥1.35b |
Cost of Revenue | CN¥1.15b |
Gross Profit | CN¥205.21m |
Other Expenses | CN¥446.18m |
Earnings | -CN¥240.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.12 |
Gross Margin | 15.15% |
Net Profit Margin | -17.79% |
Debt/Equity Ratio | 7.2% |
How did 300267 perform over the long term?
See historical performance and comparison